Debio 1562M

Preclinical

DDebiopharm International SA

Debio 1562M is one of 53 therapeutic programs targeting Acute Myeloid Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Acute Myeloid LeukemiaRecruiting

Acute Myeloid LeukemiaPreclinical

Recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Fludara

Sanofi

Phase 3

17 5

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 6

Vepesid

AAvyxa

Phase 3

52 7

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 8

Vanflyta

Daiichi Sankyo

Phase 3

14 9

Neupogen

EEastern Cooperative Oncology Group

Nexavar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

PreclinicalRecruiting

Acute Myeloid Leukemia

NCT06969430

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

A Phase 1/2, First-in-human, Multicenter, Open-label Trial Evaluating the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Recruiting·DDebiopharm International SA·Preclinical·NCT06969430·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Debio 1562M. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Debio 1562M. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Debiopharm International SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: DDebiopharm International SA

Debio 1562M

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News